The Carlat Psychiatry Podcast
Auvelity A Fast Acting Antidepressant
Feb 5, 2024
Dr. Aiken and Kellie discuss Auvelity, a fast-acting antidepressant, exploring its pharmacodynamics, benefits of pairing with bupropion, and update on treatment-resistant depression trial. They also delve into Aveleti's efficacy in depression treatment and ongoing studies.
16:44
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Auvelity combines Bute-Proprion and Dex-Tromethorphin for faster relief from depression symptoms.
- Clinical trials show Auvelity's efficacy surpassing Bute-Proprion in reducing depression symptoms in the first week.
Deep dives
The Composition of Orvellaity
Orvellaity is a combination of two older medications, Bute-Proprion and Dex-Tromethorphin. Bute-Proprion is an orepinephrine and dopamine reuptake inhibitor, while Dex-Tromethorphin increases glutamate transmission through NMDA and tagganism, similar to other third-line interventions for treatment-resistant depression. Orvellaity is the first oral antidepressant to move beyond the traditional monoamine means of serotonin, norepinephrine, and dopamine.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
